Skip to main
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies Corp is positioned for robust financial growth, primarily driven by anticipated increases in average selling prices (ASPs) and clinical mix shifts, which are expected to enhance gross profit. The transition to NovaSeq X is projected to improve sequencing margins, contributing to a favorable gross margin outlook as the company scales its capabilities. Furthermore, with incremental volume growth and ASP improvements anticipated for 2025, the financial outlook for the minimal residual disease (MRD) market is expected to strengthen, further supporting the company's revenue growth potential.

Bears say

The financial outlook for Adaptive Biotechnologies Corp indicates a stagnation in Immune Medicine revenue, with no growth anticipated as the company focuses on generating interest in its TCR-Antigen model and developing its autoimmunity program. A significant challenge arises from the data showing that approximately 25% of patients who receive an ID test do not go on to receive a minimal residual disease (MRD) test within 12 months, which negatively impacts the frequency of testing and potential revenue. Despite being recognized as a leader in the market for immune-driven medicine, the inherent limitations in patient testing rates and the flat revenue forecast contribute to a negative outlook for the company’s stock.

Adaptive Biotechnologies (ADPT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 9 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.